Active Filter(s):
Details:
Aliqopa® (copanlisib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies and now work with the FDA on a voluntary withdrawal.
Lead Product(s): Copanlisib
Therapeutic Area: Oncology Product Name: Aliqopa
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
In the Phase III trial CHRONOS-3 of 458 patients with indolent non-Hodgkin’s Lymphoma, the investigational combination of Aliqopa and rituximab was statistically significant in delaying disease progression or death compared to rituximab and placebo.
Lead Product(s): Copanlisib,Rituximab
Therapeutic Area: Oncology Product Name: Aliqopa
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2021
Details:
Phase III study CHRONOS-3 in patients with relapsed indolent Non-Hodgkin's Lymphoma (iNHL) who have received one or more prior lines of rituximab-containing therapy meets primary endpoint of progression-free survival .
Lead Product(s): Copanlisib,Rituximab
Therapeutic Area: Oncology Product Name: Aliqopa
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020